Strand Life Sciences, a subsidiary of Reliance Industries Limited, on Tuesday launched South Asia’s first Olink Explore HT proteomics service, expanding its capabilities in large-scale multi-omics research and drug discovery.

The Bengaluru-based genomics and diagnostics company said the new platform will enable researchers and pharmaceutical companies to simultaneously analyse more than 5,400 protein biomarkers from a tiny blood sample, helping accelerate disease research, biomarker discovery and precision medicine programmes.

Proteomics refers to the large-scale study of proteins, which play a key role in carrying out biological functions in the human body. The company said next-generation proteomics platforms can provide a faster and more detailed understanding of disease biology, helping researchers identify treatment pathways and potential drug targets.

“As part of this milestone, Strand has successfully completed a proteomics project for a biopharma partner involving patients with chronic kidney disease, demonstrating the platform’s potential in translational research and clinical studies,” the company said.

Dr Ramesh Hariharan, Chief Executive Officer of Strand Life Sciences, said the launch brings one of the world’s most advanced proteomics platforms to India and neighbouring regions.

“With Olink Explore HT, Strand is bringing one of the world’s most advanced proteomics platforms to India and the region,” Hariharan said.

“By combining this with established strengths in genomics, bioinformatics, and clinical partnerships, Strand aims to deliver end-to-end multi-omics programmes and enable faster, more impactful discovery,” he added.

The company said the platform would allow it to generate large multi-modal datasets across India, South Asia and West Asia through its network of hospital and clinical partners. The research programmes will focus on therapeutic areas including oncology, nephrology, metabolic diseases and rare disorders.

Strand said the new offering includes end-to-end support ranging from study design and biomarker analysis to integration with genomics and clinical datasets. The company is also looking to collaborate with global pharmaceutical, biotechnology and academic organisations for large-scale translational and discovery research programmes.

The launch comes amid growing global demand for integrated multi-omics data, an emerging area that combines genomics, proteomics and clinical information to improve drug development and precision healthcare outcomes.